PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3193822

Statistical considerations for performing multiple tests in a single experiment. 5. Comparing two therapies with respect to several endpoints.

P C O'Brien·M A Shampo
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Clinical Trials as TopicDiabetes MellitusHumansRandom AllocationStatistics as TopicComparative StudyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P C O'Brien, M A Shampo. 1988. Statistical considerations for performing multiple tests in a single experiment. 5. Comparing two therapies with respect to several endpoints.. https://doi.org/10.1016/s0025-6196(12)65511-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

New antithrombotic agents.

The development of new antithrombotic agents has been stimulated by clinical needs and by advances in biotechnology that have made it possible to produce drugs that target specific steps in thrombogenesis. Heparin has pharmacokinetic and biophysical limitations that are overcome by new anticoagulants. Of these, low-molecular-weight heparin and direct inhibitors of thrombin have been evaluated clinically. Coumarins require careful laboratory monitoring because of concerns about safety. Orally active direct inhibitors of thrombin and factor Xa may replace coumarins. Aspirin is of limited efficacy because it inhibits only one pathway of platelet activation. Inhibitors of adenosine diphosphate receptor and glycoprotein IIb/IIIa antagonists are more effective than aspirin and are used in the clinic.

Clinical Trials as Topic↗